The Potential and Pitfalls of Coronary Artery Calcium Scoring

Sadiya S. Khan; Ann Marie Navar

doi:10.1001/jamacardio.2021.4413

The Potential and Pitfalls of Coronary Artery Calcium Scoring

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	11-12
Number of pages	2
Journal	JAMA Cardiology
Volume	7
Issue number	1
DOIs	https://doi.org/10.1001/jamacardio.2021.4413
State	Published - Jan 2022

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1001/jamacardio.2021.4413

Cite this

@article{3051315fc2ad4aebbc464555f58ab3f8,

title = "The Potential and Pitfalls of Coronary Artery Calcium Scoring",

author = "Khan, {Sadiya S.} and Navar, {Ann Marie}",

note = "Funding Information: receiving grants from the American Heart Association and the National Institutes of Health outside the submitted work and being web editor for JAMA Cardiology. Dr Navar reported receiving grants from Bristol Myers Squibb, Esperion, Amgen, and Janssen; receiving personal fees from Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, CSL, Esperion, Janssen, Lilly, Sanofi, Regeneron, Novo Nordisk, Novartis, The Medicines Company, New Amsterdam, Cerner, 89bio, and Pfizer outside the submitted work; and being associate editor for JAMA Cardiology.",

year = "2022",

month = jan,

doi = "10.1001/jamacardio.2021.4413",

language = "English (US)",

volume = "7",

pages = "11--12",

journal = "JAMA Cardiology",

issn = "2380-6583",

publisher = "American Medical Association",

number = "1",

}

TY - JOUR

T1 - The Potential and Pitfalls of Coronary Artery Calcium Scoring

AU - Khan, Sadiya S.

AU - Navar, Ann Marie

N1 - Funding Information: receiving grants from the American Heart Association and the National Institutes of Health outside the submitted work and being web editor for JAMA Cardiology. Dr Navar reported receiving grants from Bristol Myers Squibb, Esperion, Amgen, and Janssen; receiving personal fees from Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, CSL, Esperion, Janssen, Lilly, Sanofi, Regeneron, Novo Nordisk, Novartis, The Medicines Company, New Amsterdam, Cerner, 89bio, and Pfizer outside the submitted work; and being associate editor for JAMA Cardiology.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85118593303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118593303&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2021.4413

DO - 10.1001/jamacardio.2021.4413

M3 - Editorial

C2 - 34705021

AN - SCOPUS:85118593303

SN - 2380-6583

VL - 7

SP - 11

EP - 12

JO - JAMA Cardiology

JF - JAMA Cardiology

IS - 1

ER -

The Potential and Pitfalls of Coronary Artery Calcium Scoring

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this